Abstract library

12 results for "Quaglia".
#3018 Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?
Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Dr Julian Gertner
Keywords: telotristat
#3021 Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients’ Experience
Introduction: In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Julian Gertner
Keywords: homecare
#455 Depression and Carcinoid Syndrome: Is There Any Relationship? A Cross-Sectional Study
Introduction: The relationship between brain serotonin and depression is well-established. It is also widely accepted that serotonin hyperproduction in carcinoid syndrome does not cross the brain barrier. CNS serotonin is synthesised from tryptophan within serotonergic neurons and a deficiency of this precursor could be possible on carcinoid patients.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Jorge Garcia-Hernandez
#683 Liver Resection Experience for Metastatic Small Bowel NETs, a Single Center Experience
Introduction: Over the last two decades, the role of surgery in the management of small bowel NETs (SBNET) has evolved. There is growing evidence supporting the role of liver resection for metastatic disease.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Raj Srirajaskanthan
#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary
Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Surgical treatment
Presenting Author: Dr Raj Srirajaskanthan
#890 Prognostic Validity of the WHO 2010 TNM Staging and Grading Criteria for Pancreatic Neuroendocrine Tumors
Introduction: The TNM staging and grading system developed by the WHO was designed to help prognosticate patients.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Mr Logan E Mills
#893 The Role of Primary Resection and Hepatic Resection in the Management of Metastatic Pancreatic Neuroendocrine Tumors with Irresectable Liver Metastases
Introduction: More than 40% of pancreatic neuroendocrine tumor (PNET) patients have liver metastases (LM) at diagnosis. Whilst it is agreed that, where possible, curative surgery offers the best outcomes, the role of debulking surgery in the context of irresectable LM remains unclear.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: Mr Logan E Mills
Keywords: liver
#1209 Pancreatic Neuroendocrine Incidentalomas: When is Surgery in the Patient’s Best Interests?
Introduction: Small PNETs, many of which are diagnosed incidentally, pose a management dilemma. Whilst resection offers curative outcomes, the risks of surgery have led many to adopt surveillance strategies. 2cm is often used as a threshold for malignancy, but reports suggest that this value may not be valid.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: Logan Mills
Keywords: PNET
#1233 CA 19-9: A Novel Role in the Prognosis of Pancreatic Neuroendocrine Tumors
Introduction: Prognostication is difficult for neuroendocrine tumours given their long survival. Staging, grading using Ki67 and receptor status are tools commonly used, but are not without their limitations. CA 19-9 is a tumour marker used in the diagnosis and follow-up of pancreatic adenocarcinomas despite multiple confounding factors, including jaundice. CA 19-9 is not useful in the diagnosis of PNETs having a sensitivity of only 19%, but it is not known whether it has other roles in PNETs.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Logan Mills
Authors: Mills L, Ramage J, Quaglia A, Basuroy R, ...
Keywords: CA 19-9
#1239 Histological Classification of Pancreatic Neuroendocrine Tumours: Optimising the Ki67 System
Introduction: Pancreatic neuroendocrine tumours are graded using the Ki67 antigen in accordance with the WHO 2010 classification. Despite the system’s widespread use, a wide variety of tumour behaviours have been described leading to various proposed revisions.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Pathology, grading, staging
Presenting Author: Logan Mills
Keywords: G3